Key Points
NEW DELHI: While the government is all set to introduce a draft of the New Drugs, Medical Devices and Cosmetics Bill seeking to repeal 83-year-old Drugs and Cosmetics Act in the monsoon session of the Parliament that starts this week, a key stakeholder says not enough discussions have been held and it should be recalled...
The Association of Indian Medical Device Industry (AiMed), wrote to the Union health minister Mansukh Mandaviya on Tuesday, urging to recall the draft bill..
After the initial invitation of comments we have not been invited for any discussions or the revised draft was not shared with us, said Rajiv Nath, forum co-ordinator, AiMed...
Stating that they are highly dismayed that the government has tabled the Draft of New Drugs, Medical Devices and Cosmetics Bill, 2022 for introduction, consideration and passing to the Parliament for the monsoon session to regulate drugs and medical devices without even a single meeting with them as major stakeholders, in a letter to Mandaviya, Nath said that the move has been made in astrange manner...
He has, therefore, urged the minister to recall the draft bill with an advisory to resubmit as separate laws for regulating drugs and medical devices and after having followed the due consultative, democratic process...
You might be interested in
Health Ministry moots Centre or state bodies be empowered to regulate drugs, cosmetics manufacture
19, Jul, 23The draft New Drugs, Medical Devices and Cosmetics Bill, 2023, has a separate chapter on AYUSH medicines, proposing for the first time to regulate Sowa Rigpa and homoeopathy.
Slammed by industry, drugs bill set to get delayed as govt plans fresh panel for review
21, Aug, 23The Drugs, Medical Devices and Cosmetics Bill, 2023, is being planned as a substitute for the existing drug law, which was passed during the pre-Independence period.
New drugs regulatory bill may be headed for cabinet next week
12, Aug, 23The Bill seeks to regulate the import, manufacture, distribution and sale of drugs, medical devices and cosmetics. It also seeks to ensure their quality, safety, efficacy, performance and clinical trials of new drugs and clinical investigation of investigational medical devices and clinical performance evaluation of new in-vitro diagnostic medical devices, including Ayurveda, Unani, Siddha, Sowa-Rigpa and homeopathy (AUSSH) drugs, medical devices and cosmetics.